- Email: [email protected]
Mass spectrometry imaging and tissue microproteomic for clinical applications
Abstracts / Journal of Biotechnology 185S (2014) S5–S17
Present and future trends in the animal biotechnology sector Edo Dagaro DIAL, University of Udine, Italy E-mail address: [email protected]. In the last two decades, genomic research in farm animals has greatly improved our knowledge on the genetic control of the most important production, reproduction and fitness traits. Results have already been applied in breeding programs in order to improve production and reproduction efficiency and reduce disease incidence. Many traits of economic importance in livestock animals are quantitative and traditionally, the genetic improvement has been based on complex statistical methods. Recent developments in the beadchip DNA technology have made possible to identify, in the most important farm animal species, a large number of single point mutations (SNPs) at the sequence level and to link them to the observed phenotypic variability. In the near future, several genomic applications (Beadchip DNA, Whole Exome Sequencing, Next Generation Sequencing, RNA-seq) will be sufficiently fast, accurate and cheap to be used in routine animal breeding practices. http://dx.doi.org/10.1016/j.jbiotec.2014.07.039 Mass spectrometry imaging and tissue microproteomic for clinical applications Michel Salzet ∗ , Maxence Wisztorski, Julien Franck, Eric Leblanc, Denis Vinatier, Isabelle Farré, Isabelle Fournier Laboratoire Protéomique, Réponse Inflammatoire, Spectrométrie de masse – EA 4550, Université Lille, France E-mail address: [email protected] (M. Salzet). Recent developments in the field of MALDI MSI make nowadays this technology a unique tool for various applications in ranging from fundamental biology to translational thematic in clinics. For this late aspect MALDI shows to be very useful for hunting markers of physiopathological stages using prospective or retrospective ways in a perspective of diagnostic or prognostic. MALDI MSI can even bring comprehension of the mechanisms underlying pathologies evolution if images compounds are tightly related to their identification. In this respect, it was shown that both a comprehensive study of lipids, peptides and proteins regulation and localization variations during physiopathological processes can bring important information. Such strategies were applied to study different pathological contexts either in the field of oncology (Ovarian Cancer) or in neurosciences (Parkinson, Epilepsy, Alzheimer, neuroregeneration). All together, these examples clearly show that MALDI MSI become an important technology in translational clinical researches. http://dx.doi.org/10.1016/j.jbiotec.2014.07.040
S11
Biological markers for bladder cancer Mariapia Viola Magni 1,∗ , Samuela Cataldi 2 1 Fondazione Enrico Puccinelli, Via Cestellini, 3 Ponte S. Giovanni, 06135 Perugia, Italy 2 Dipartimento Farmaceutiche, Università di Perugia, Via A. Fabretti 48, 06123 Perugia, Italy
E-mail address: [email protected] (M.V. Magni). Urothelial bladder carcinoma causes 150,000 deaths every year and there is not efficient treatment until now. The diagnosis can be made only with cystoscopy which is invasive. An attempt is made to find other diagnostic means which may help in diagnosis and in monitoring during the treatment. Recently a molecular analysis was made on 131 urothelial carcinomas and mutations were found in 32 genes which are involved in cell-cycle chromatin and signalling pathways regulation. Sequences of RNA, identification of miRNA and proteomic analysis was also made without finding a marker which have sufficient sensitivity and specificity. Considering that nucleic acids are released in all biological fluids, it has suggested to use the urine to identify a possible biological marker. Many researchers identify different markers isolated from the voided urine or from the sediment in the last five years without reaching a conclusive proposal. The isolation of nucleic acids from voided urine after high speed centrifugation demonstrates that the amount of protein, RNA and DNA is reduced with respect to the same particles isolated from lymphocytes in culture whereas lipids remain. Fatty acids are present and it is shown some differences between healthy control and patients opening perhaps new diagnostic means. http://dx.doi.org/10.1016/j.jbiotec.2014.07.041 Cancer genomics and biomarker discovery Hilal Özda˘g Biotechnology Institute, Ankara University, Ankara, Turkey E-mail address: [email protected]. Cancer is a multigenic, multifactorial and a very heterogenous disease. This heterogeneity complicates diagnosis and targeted therapy of cancer. Philadelphia chromosome, BCR-ABL fusion, was identified in 1970s. In 1999s, tyrosine kinase inhibitor drugs were approved by FDA to be used in the therapy of BCR-ABL bearing leukemia patients. The complex genetic background of cancer has long been known. But until the completion of human genome project and the development of genomics technologies the means to discover cancer genome was restricted. Initially with microarray technology and recently with next generation technology, the Cancer Genome Project and The Cancer Genome Atlas along with several other individual cancer genomics projects gathered crucial information on cancer biology and its molecular profile. Starting at 2007, we have been conducting projects on sporadic colorectal cancer genomics. In these projects a family based genome-wide association analysis study was accomplished and candidate predisposition loci was identified. In the following steps of the project, gene expression profiling (GEP) and array comparative genomic hybridization (aCGH) analyses were performed on tumour/normal pair tissue samples. Integrative analysis of GEP and aCGH results points out novel and previously reported gene loci
Present and future trends in the animal biotechnology sector Edo Dagaro DIAL, University of Udine, Italy E-mail address: [email protected]. In the last two decades, genomic research in farm animals has greatly improved our knowledge on the genetic control of the most important production, reproduction and fitness traits. Results have already been applied in breeding programs in order to improve production and reproduction efficiency and reduce disease incidence. Many traits of economic importance in livestock animals are quantitative and traditionally, the genetic improvement has been based on complex statistical methods. Recent developments in the beadchip DNA technology have made possible to identify, in the most important farm animal species, a large number of single point mutations (SNPs) at the sequence level and to link them to the observed phenotypic variability. In the near future, several genomic applications (Beadchip DNA, Whole Exome Sequencing, Next Generation Sequencing, RNA-seq) will be sufficiently fast, accurate and cheap to be used in routine animal breeding practices. http://dx.doi.org/10.1016/j.jbiotec.2014.07.039 Mass spectrometry imaging and tissue microproteomic for clinical applications Michel Salzet ∗ , Maxence Wisztorski, Julien Franck, Eric Leblanc, Denis Vinatier, Isabelle Farré, Isabelle Fournier Laboratoire Protéomique, Réponse Inflammatoire, Spectrométrie de masse – EA 4550, Université Lille, France E-mail address: [email protected] (M. Salzet). Recent developments in the field of MALDI MSI make nowadays this technology a unique tool for various applications in ranging from fundamental biology to translational thematic in clinics. For this late aspect MALDI shows to be very useful for hunting markers of physiopathological stages using prospective or retrospective ways in a perspective of diagnostic or prognostic. MALDI MSI can even bring comprehension of the mechanisms underlying pathologies evolution if images compounds are tightly related to their identification. In this respect, it was shown that both a comprehensive study of lipids, peptides and proteins regulation and localization variations during physiopathological processes can bring important information. Such strategies were applied to study different pathological contexts either in the field of oncology (Ovarian Cancer) or in neurosciences (Parkinson, Epilepsy, Alzheimer, neuroregeneration). All together, these examples clearly show that MALDI MSI become an important technology in translational clinical researches. http://dx.doi.org/10.1016/j.jbiotec.2014.07.040
S11
Biological markers for bladder cancer Mariapia Viola Magni 1,∗ , Samuela Cataldi 2 1 Fondazione Enrico Puccinelli, Via Cestellini, 3 Ponte S. Giovanni, 06135 Perugia, Italy 2 Dipartimento Farmaceutiche, Università di Perugia, Via A. Fabretti 48, 06123 Perugia, Italy
E-mail address: [email protected] (M.V. Magni). Urothelial bladder carcinoma causes 150,000 deaths every year and there is not efficient treatment until now. The diagnosis can be made only with cystoscopy which is invasive. An attempt is made to find other diagnostic means which may help in diagnosis and in monitoring during the treatment. Recently a molecular analysis was made on 131 urothelial carcinomas and mutations were found in 32 genes which are involved in cell-cycle chromatin and signalling pathways regulation. Sequences of RNA, identification of miRNA and proteomic analysis was also made without finding a marker which have sufficient sensitivity and specificity. Considering that nucleic acids are released in all biological fluids, it has suggested to use the urine to identify a possible biological marker. Many researchers identify different markers isolated from the voided urine or from the sediment in the last five years without reaching a conclusive proposal. The isolation of nucleic acids from voided urine after high speed centrifugation demonstrates that the amount of protein, RNA and DNA is reduced with respect to the same particles isolated from lymphocytes in culture whereas lipids remain. Fatty acids are present and it is shown some differences between healthy control and patients opening perhaps new diagnostic means. http://dx.doi.org/10.1016/j.jbiotec.2014.07.041 Cancer genomics and biomarker discovery Hilal Özda˘g Biotechnology Institute, Ankara University, Ankara, Turkey E-mail address: [email protected]. Cancer is a multigenic, multifactorial and a very heterogenous disease. This heterogeneity complicates diagnosis and targeted therapy of cancer. Philadelphia chromosome, BCR-ABL fusion, was identified in 1970s. In 1999s, tyrosine kinase inhibitor drugs were approved by FDA to be used in the therapy of BCR-ABL bearing leukemia patients. The complex genetic background of cancer has long been known. But until the completion of human genome project and the development of genomics technologies the means to discover cancer genome was restricted. Initially with microarray technology and recently with next generation technology, the Cancer Genome Project and The Cancer Genome Atlas along with several other individual cancer genomics projects gathered crucial information on cancer biology and its molecular profile. Starting at 2007, we have been conducting projects on sporadic colorectal cancer genomics. In these projects a family based genome-wide association analysis study was accomplished and candidate predisposition loci was identified. In the following steps of the project, gene expression profiling (GEP) and array comparative genomic hybridization (aCGH) analyses were performed on tumour/normal pair tissue samples. Integrative analysis of GEP and aCGH results points out novel and previously reported gene loci